| Title |
Bee venom in cancer therapy
|
|---|---|
| Published in |
Cancer and Metastasis Reviews, November 2011
|
| DOI | 10.1007/s10555-011-9339-3 |
| Pubmed ID | |
| Authors |
Nada Oršolić |
| Abstract |
Bee venom (BV) (api-toxin) has been widely used in the treatment of some immune-related diseases, as well as in recent times in treatment of tumors. Several cancer cells, including renal, lung, liver, prostate, bladder, and mammary cancer cells as well as leukemia cells, can be targets of bee venom peptides such as melittin and phospholipase A2. The cell cytotoxic effects through the activation of PLA2 by melittin have been suggested to be the critical mechanism for the anti-cancer activity of BV. The induction of apoptotic cell death through several cancer cell death mechanisms, including the activation of caspase and matrix metalloproteinases, is important for the melittin-induced anti-cancer effects. The conjugation of cell lytic peptide (melittin) with hormone receptors and gene therapy carrying melittin can be useful as a novel targeted therapy for some types of cancer, such as prostate and breast cancer. This review summarizes the current knowledge regarding potential of bee venom and its compounds such as melittin to induce cytotoxic, antitumor, immunomodulatory, and apoptotic effects in different tumor cells in vivo or in vitro. The recent applications of melittin in various cancers and a molecular explanation for the antiproliferative properties of bee venom are discussed. |
X Demographics
The data shown below were collected from the profiles of 1,911 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 418 | 22% |
| United States | 24 | 1% |
| Austria | 6 | <1% |
| Thailand | 5 | <1% |
| United Kingdom | 4 | <1% |
| China | 4 | <1% |
| Australia | 3 | <1% |
| Canada | 3 | <1% |
| Solomon Islands | 3 | <1% |
| Other | 18 | <1% |
| Unknown | 1423 | 74% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1906 | 100% |
| Practitioners (doctors, other healthcare professionals) | 3 | <1% |
| Scientists | 1 | <1% |
| Unknown | 1 | <1% |
Mendeley readers
The data shown below were compiled from readership statistics for 303 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 3 | <1% |
| Sweden | 1 | <1% |
| Turkey | 1 | <1% |
| India | 1 | <1% |
| Croatia | 1 | <1% |
| Unknown | 296 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 39 | 13% |
| Student > Master | 39 | 13% |
| Student > Bachelor | 39 | 13% |
| Researcher | 31 | 10% |
| Student > Postgraduate | 14 | 5% |
| Other | 42 | 14% |
| Unknown | 99 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 53 | 17% |
| Biochemistry, Genetics and Molecular Biology | 50 | 17% |
| Medicine and Dentistry | 23 | 8% |
| Chemistry | 22 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 17 | 6% |
| Other | 25 | 8% |
| Unknown | 113 | 37% |
Attention Score in Context
This research output has an Altmetric Attention Score of 759. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 April 2024.
All research outputs
#26,368
of 25,782,917 outputs
Outputs from Cancer and Metastasis Reviews
#1
of 881 outputs
Outputs of similar age
#78
of 247,292 outputs
Outputs of similar age from Cancer and Metastasis Reviews
#1
of 20 outputs
Altmetric has tracked 25,782,917 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 881 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.5. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 247,292 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 20 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.